-
Product Insights
Influenzavirus A Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Influenzavirus A Infections - Drugs In Development, 2023’, provides an overview of the Influenzavirus A Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Influenzavirus A Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Genital Herpes – Drugs In Development, 2023
Global Markets Direct’s, ‘Genital Herpes - Drugs In Development, 2023’, provides an overview of the Genital Herpes pipeline landscape. The report provides comprehensive information on the therapeutics under development for Genital Herpes, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Cervical Intraepithelial Neoplasia (CIN) – Drugs In Development, 2023
Global Markets Direct’s, ‘Cervical Intraepithelial Neoplasia (CIN) - Drugs In Development, 2023’, provides an overview of the Cervical Intraepithelial Neoplasia (CIN) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cervical Intraepithelial Neoplasia (CIN), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Norovirus Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Norovirus Infections - Drugs In Development, 2023’, provides an overview of the Norovirus Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Norovirus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Influenza A Virus, H5N1 Subtype Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Influenza A Virus, H5N1 Subtype Infections - Drugs In Development, 2023’, provides an overview of the Influenza A Virus, H5N1 Subtype Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Influenza A Virus, H5N1 Subtype Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
NewNet Present Value Model: Vaxart Inc’s Norovirus [strains Norwalk GI.1 + Sydney GII.4] (bivalent) vaccine
Empower your strategies with our Net Present Value Model: Vaxart Inc's Norovirus [strains Norwalk GI.1 + Sydney GII.4] (bivalent) vaccine report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – 0.75 Percent Nyxol Eye Drop in Mydriasis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - 0.75 Percent Nyxol Eye Drop in Mydriasis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.0.75 Percent Nyxol Eye Drop in MydriasisDrug Details: Phentolamine mesylate...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – QLS-111 in Normal-Tension Glaucoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - QLS-111 in Normal-Tension Glaucoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. QLS-111 in Normal-Tension Glaucoma Drug Details: QLS-111 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Norovirus [Strains Norwalk Gi.1 + Sydney Gii.4] (Bivalent) Vaccine in Norovirus Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Norovirus [Strains Norwalk Gi.1 + Sydney Gii.4] (Bivalent) Vaccine in Norovirus Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Norovirus [Strains Norwalk Gi.1 +...